SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: WHL who wrote (26)3/27/1998 9:57:00 PM
From: dipper  Respond to of 946
 
I held MATX at 3 1/4 from Nov 97. 15 cents above end of year cash position. MATX had many more disappointments than CTIC. Got out at 4 7/8 two weeks ago after an investor meeting took place in Phoenix three weeks ago. It's all about exposure and patience. I'll take this extremely low risk situation any time. My opinion is that there are plenty of disappoiting biotechs that trade much higher than CTIC and management sells, not buys like they did recently in the low teens.



To: WHL who wrote (26)4/1/1998 8:16:00 PM
From: dipper  Read Replies (1) | Respond to of 946
 
Management meeting with JNJ beginning tomorrow. Four weeks of review of the trial data to follow. Management will have comments after that to elaborate on any positives from the study ( Including further evidence to support the "skewed results" opinions). Also, management is locked out of buying stock until roughly mid-May. Remember, 4 members of management purchased recently at prices from 12.38 - 15.00.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News